BiotechTube
A2A Pharma

A2A Pharma

Phase 1
Cambridge, United StatesFounded 2017a2apharma.com

A2A Pharmaceuticals is a private, AI-driven drug discovery company focused on developing first-in-class therapeutics for life-threatening diseases, with a core emphasis on oncology. The company has achieved key milestones, including advancing its lead TACC3 inhibitor (AO-252) into Phase 1 clinical trials with early signs of efficacy and forming strategic partnerships with Biomea Fusion and Johnson & Johnson. Utilizing its SCULPT™ platform, A2A systematically designs novel chemical libraries to drug challenging targets, building a pipeline that includes inhibitors of MLL-Menin, TYK2 pseudokinase, YAP-TEAD, and a KRAS degrader.

Market Cap
Private
Pipeline
—
Patents
—
Publications
—

Private Company

Funding information not available

AI Company Overview

A2A Pharmaceuticals is a private, AI-driven drug discovery company focused on developing first-in-class therapeutics for life-threatening diseases, with a core emphasis on oncology. The company has achieved key milestones, including advancing its lead TACC3 inhibitor (AO-252) into Phase 1 clinical trials with early signs of efficacy and forming strategic partnerships with Biomea Fusion and Johnson & Johnson. Utilizing its SCULPT™ platform, A2A systematically designs novel chemical libraries to drug challenging targets, building a pipeline that includes inhibitors of MLL-Menin, TYK2 pseudokinase, YAP-TEAD, and a KRAS degrader.

OncologyAutoimmune DiseasesInfectious DiseasesMuscular Dystrophy

Technology Platform

SCULPT™ (Systematic Combinatorial Unification of chemical groups into Libraries against a Pharmacological Target) is a proprietary, AI-enhanced computational platform that designs novel, target-specific small-molecule libraries from first principles, optimizing for drug-like properties and target engagement.

Opportunities

The lead TACC3 inhibitor has a first-in-class mechanism with early clinical promise, creating a significant opportunity in aggressive women's cancers.
The SCULPT platform can generate valuable IP for multiple high-value, difficult targets (YAP-TEAD, pan-KRAS), offering partnership or internal development opportunities.
The autoimmune TYK2 program addresses a large market with a potential best-in-class safety profile.

Risk Factors

The company's clinical-stage pipeline is early (Phase 1), and the novel mechanisms carry unproven efficacy and safety risks.
Financial resources are limited (~$8M raised), necessitating heavy reliance on partnerships and dilutive future financing.
Competition is intense in several target areas (MLL-Menin, TYK2), requiring clear differentiation.

Competitive Landscape

A2A's lead TACC3 program is first-in-class with no direct clinical competitors. However, its other programs face established rivals: Biomea/Kura in MLL-Menin, Bristol Myers Squibb in TYK2, and several biotechs in YAP-TEAD and KRAS. Its key differentiation is the SCULPT platform's ability to design novel chemistry against these difficult protein-protein interaction targets.